TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy - Summary - MDSpire

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy

  • By

  • Carolina Kessler

  • Melanie von Brandenstein

  • Niklas Klümper

  • Philipp Krausewitz

  • Enno Storz

  • Constantin Rieger

  • Laurenz Sperber

  • Pia Paffenholz

  • Yuri Tolkach

  • Ralph Wirtz

  • Markus Eckstein

  • Axel Heidenreich

  • Richard Weiten

  • September 1, 2025

  • 0 min

Share

Objective:

Add significance of TROP-2 in nccRCC.

Key Findings:
  • Incorporate specific data points or statistics.
Interpretation:

Expand on clinical implications of TROP-2 overexpression.

Limitations:
  • Include potential confounding factors.
Conclusion:

Reiterate the importance of further research more compellingly.

Original Source(s)

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy

  • by Carolina Kessler, Melanie von Brandenstein, Niklas Klümper, Philipp Krausewitz, Enno Storz, Constantin Rieger, Laurenz Sperber, Pia Paffenholz, Yuri Tolkach, Ralph Wirtz, Markus Eckstein, Axel Heidenreich, Richard Weiten

  • September 1, 2025

Related Content

Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128)

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

  • November 5, 2025

  • 1 min
Adjuvant Treatment Approaches for Renal Cell Carcinoma: Insights from Historical Challenges and Emerging Possibilities with Immune Checkpoint Inhibitors